Clinical trial · Observational
Evaluatıon of sympathetıc Nervous System fındıngs and theır relatıonshıp wıth Symptoms ın patıents wıth Breast Cancer Related Lymphedema
NCT07019740CI-TRIAL-00090976completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to evaluate the sympathetic nervous system, small fiber functions and autonomic symptoms in patients with breast cancer related lymphedema and to investigate the relationship between these findings and patients' symptoms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphedema, Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CASE GROUP | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CASE GROUP
- description
- BREAST CANCER RELATED LYPMHEDEMA
- interventionNames
- Other: CASE GROUP
- label
- CONTROL GROUP
- description
- HEALTHY GROUP
- interventionNames
- Other: CASE GROUP
Primary outcomes (5)
- measure
- SSR latency in affected and unaffected arms of patient with breast cancer related lymphedema
- timeFrame
- Day 1
- description
- Sympathetic skin response (SSR) latency will be recorded bilaterally using standard surface electrodes placed on the palm and dorsum of the hand. Electrical stimulation will be applied to the median nerve at the wrist with parameters of 20-30 mA and 0.2 ms pulse duration. Latency is defined as the time between stimulus and onset of the first deflection in the recording and will be expressed in milliseconds.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient age group between 18-75 years * To have been diagnosed with breast cancer-related lymphedema by imaging and/or clinical diagnostic methods Exclusion Criteria: History of upper extremity lymphedema due to causes other than breast cancer * Lymphedema in other body parts * Diagnosis of polyneuropathy or entrapment neuropathy in the upper extremity * Presence of active infection at the assessment site * Presence of congenital or acquired malformations at the evaluation site * Those with any medical condition that may cause edema, such as severe heart or kidney failure
References
Publications (0)
Data not yet available
No reference posted for this study.